fda compounding semaglutide warning 2025 october issued 25 letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA Warns on Certain Forms

Victoza was approved in 2010, but in 2013, the FDA issued a warning to consumers of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas. But we dont have to look at previous generations of GLP-1s so see the risk that unknown side effects have

PlexusDx requires no membership fees or insurance, is HSA/FSA eligible, and serves all 50 states

The dosage comparison between retatrutide and tirzepatide shows that retatrutide achieves similar or superior outcomes at comparable or lower milligram doses

Each has unique benefits and considerations, making it crucial to have a detailed discussion with your healthcare provider to determine the best fit for your health goals

less frequent dosing Feature Combined references BPC-157 Often paired with TB-500 in community planning ('Wolverine stack') TB-500 Same pairing Feature Regulatory status BPC-157 Removed from FDA Category 2 April 22, 2026